TPD eliminates pathogenic proteins by engaging endogenous proteolytic systems. The abstract contrasts this with conventional inhibition that only transiently blocks enzymatic activity.
First-pass extracted concept
targeted protein degradation
Candidate: concept label3 source documents5 linked claims
Live refresh every 5sNext refresh in 5s
Aliases
TPD
Extracted Explainers
What the tool is doing
What problem it solves
Evidence Snippets
Targeted protein degradation (TPD) has reshaped therapeutic strategy by catalytically eliminating pathogenic proteins through engagement with endogenous proteolytic systems.
PROTACs have been revolutionary in drug development rendering targeted protein degradation (TPD) as an emerging therapeutic modality.
The title names "targeted protein degraders" and the supplied summary states that the review is a broad review on targeted protein degradation centered on heterobifunctional PROTACs.
Supporting Sources
Linked Claims
Compared with conventional inhibitors, targeted protein degradation achieves durable target silencing by removing the protein entirely and can overcome resistance mechanisms.
Quoted textsource-backed
In contrast to conventional inhibitors that transiently block enzymatic activity, TPD achieves durable target silencing by physically removing the protein entirely, thereby overcoming resistance mechanisms and extending therapeutic durability.
Existing targeted protein degradation platforms including PROTACs and molecular glues are limited in clinical translation by poor bioavailability, off-target toxicity, and suboptimal tissue selectivity.
Quoted textsource-backed
However, clinical translation of existing TPD platforms, including PROTACs and molecular glues, remains limited by poor bioavailability, off-target toxicity, and suboptimal tissue selectivity.
Targeted protein degradation catalytically eliminates pathogenic proteins through engagement with endogenous proteolytic systems.
Quoted textsource-backed
Targeted protein degradation (TPD) has reshaped therapeutic strategy by catalytically eliminating pathogenic proteins through engagement with endogenous proteolytic systems.
Targeted protein degradation enables pharmacological modulation of previously undruggable entities such as transcription factors and scaffolding proteins.
Quoted textsource-backed
This approach enables the pharmacological modulation of previously "undruggable" entities, such as transcription factors and scaffolding proteins, that lack canonical binding pockets.
This review is centered on heterobifunctional PROTACs within the broader targeted protein degradation field and also discusses adjacent modalities such as molecular glues.